Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...